AUTHORS
Rafal Asmaro, MD, Roy Khalife, MD, MHPE2, M. Dawn Goodyear, MD, MSc, FRCPC3, Michelle Sholzberg, MD4, Paula James, MD5, Natalia Rydz6, Kelsey Uminski, MD, MPrecH, FRCPC7
AFFILIATIONS
1 University of Calgary, Calgary, Alberta, Canada
2 University of Ottawa, Ottawa, Canada
3 University of Calgary, Calgary, Alberta, Canada
4 University of Toronto, Toronto, Ontario, Canada
5 Queen's University, Kingston, Ontario, Canada
6 University of Calgary, Calgary, Alberta, Canada
7 University of Calgary, Calgary, Alberta, Canada
ABSTRACT
Introduction: Bleeding disorder of unknown cause (BDUC) describes patients with a clinically significant bleeding phenotype despite normal standard hemostatic investigations. The International Society on Thrombosis and Haemostasis (ISTH) published recommendations to standardize BDUC terminology and diagnostic evaluation, including essential first-line investigations and additional specialized testing where available. The uptake of these recommendations, availability of specialized testing, and their incorporation into routine clinical care remain unknown. We conducted a national survey to characterize Canadian diagnostic practices for BDUC and identify gaps between guidelines and clinical practice.
Methods: An anonymous electronic survey was distributed to physician members of the Association of Hemophilia Clinic Directors of Canada in March 2026 and remained open for 10 weeks. The survey assessed diagnostic approaches to BDUC, including terminology, laboratory investigations, and availability and perceived utility of specialized testing. Responses were summarized using descriptive statistics.
Results: Twenty-four physicians (54% adult, 33% pediatric, 13% both) representing treatment centres in 9 provinces across Canada responded; 58% had practiced in hemostasis for ≥5 years, and 63% had cared for ≥10 patients with BDUC in the preceding 12 months. Nearly all respondents (96%) used the term BDUC, when referring to patients with an abnormal bleeding phenotype and no identifiable cause after standard hemostatic testing. Sixty-nine percent supported follow-up of BDUC patients within hemophilia or bleeding disorders treatment centres. Joint hypermobility was assessed most or all the time by 65%; among those performing assessments, 73% routinely used a formal tool, most commonly the Beighton score. Initial investigations reported by ≥50% of respondents included: complete blood count, peripheral blood smear, mean platelet volume, creatinine, liver enzymes, ABO blood group, partial thromboplastin time (PTT), prothrombin time, factor VIII (clot-based), von Willebrand factor (VWF) activity, VWF antigen and fibrinogen. Factor IX and XI testing were included as first-line investigations by 30% and 35% of respondents, respectively. Among second-line investigations, only platelet aggregation studies were reported by ≥50% of respondents. Assessment for platelet dense granule deficiency (by platelet electron microscopy or platelet secretion assays) was reported by 9% of respondents in the first-line setting and 32% in the second-line setting. Access to specialized fibrinolytic testing (clot lysis time, plasminogen activator inhibitor-1 activity, tissue plasminogen activator antigen, and α2-antiplasmin activity) was uncertain for most respondents. Although 63% agreed these investigations could meaningfully aid the diagnosis of BDUC, fewer believed they meaningfully informed clinical management. Access to specialized global hemostasis assays was limited. Thrombin generation assays were unavailable onsite, while access to ROTEM/TEG and platelet function analyzers varied and was often restricted to specific clinical settings. Most respondents were neutral regarding their clinical utility. Multigene panel testing and whole-exome sequencing most commonly required out-of-country referral. Although 54% of respondents agreed these investigations could meaningfully aid the diagnosis of BDUC, fewer (33%) perceived them to meaningfully inform clinical management. Overall, 91% agreed that a national resource of diagnostic testing pathways and referral options would be useful.
Conclusions: Canadian hemostasis physicians demonstrate alignment with ISTH recommendations for BDUC diagnosis, with broad uptake of standardized terminology and generally consistent first-line investigations. Potential opportunities for greater alignment include more routine assessment for platelet dense granule deficiency and consideration of factor IX and XI testing, although local laboratory practices and PTT assay performance may influence investigation strategies. Availability and perceived utility of specialized investigations varied, highlighting uncertainty regarding their role in BDUC. Despite the limitations of self-reported practice and potential selection bias, these findings support development of a Canadian BDUC diagnostic resource outlining testing pathways, specialized investigation availability, and referral options to promote consistent care across Canada.
DISCLOSURES
Rafal Asmaro, MD: No relevant conflicts of interest to declare.